Coherus Oncology (CHRS) Other Non-Current Assets (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Other Non-Current Assets data on file, last reported at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 36.51% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (down 36.51% YoY), and the FY2025 full-year result was $4.1 million, down 94.38% from the prior year.
• Other Non-Current Assets slipped to $3.6 million in Q1 2026, from $4.1 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $72.2 million in Q4 2024 to a low of $3.6 million in Q1 2026.
• A 5-year average of $11.2 million and a median of $7.8 million in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets soared 645.2% in 2024 and slumped 94.38% in 2025, its largest moves.
• Tracing CHRS's Other Non-Current Assets over 5 years: stood at $8.7 million in 2022, then advanced by 11.74% to $9.7 million in 2023, then soared by 645.2% to $72.2 million in 2024, then tumbled by 94.38% to $4.1 million in 2025, then fell by 11.4% to $3.6 million in 2026.
• Business Quant data shows CHRS's Other Non-Current Assets at $3.6 million in Q1 2026, $4.1 million in Q4 2025, and $4.4 million in Q3 2025.